Plain-English translation of NCT06280313 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a combination approach for patients with advanced liver cancer (hepatocellular carcinoma) that cannot be surgically removed. The study involves removing your spleen through surgery, then starting two medications: Tislelizumab, an immune-boosting drug given by IV infusion, and Lenvatinib, a targeted cancer drug taken as a daily pill. The goal is to see if this combination helps slow or stop cancer growth in people whose livers are also scarred and have complications from that scarring.
People with advanced liver cancer and severe liver scarring often have limited treatment options. Removing the spleen may help improve how well the immune system and targeted medications work together, potentially offering better results than these drugs alone.
You likely qualify if…
You likely don't qualify if…
You would first undergo spleen removal surgery, performed either as open surgery or through small incisions (laparoscopic). Two weeks after surgery, you would start receiving Tislelizumab by IV infusion every three weeks. One week later, you would begin taking Lenvatinib as a daily pill (dose based on your body weight). You would continue both medications until your cancer progresses, you experience side effects you cannot tolerate, or the study team determines it's time to stop. You would have regular visits to monitor how well the treatment is working and check for any side effects.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
China